Treatment Access News
Drugs evaluated by CDR and pCODR no longer require review by CED
march 24, 2016
On March 23rd, Ontario Public Drugs Program (OPDP) announced that (effective APRIL 1st, 2016) anything evaluated by the CDR or pCODR (the oncology division of the CDR) will not REQUIRE an additional review by the CED (Committee to Evaluate Drugs).
This announcement is welcomed by CTAC as often, provinces doing the CDR process again through the CED can be duplicative.
This change in process indicates that provinces and territories can always elect to do a provincial review at their discretion. The change is intended to help streamline federal-to-provincial processes.